Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 8/20 | 0.38 |
| ▸ | PTGES | O14684 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 2/20 | 0.35 |
| ▸ | PPARA | Q07869 | 2/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.34 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | PTPRO | Q16827 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1852638 | 0.88 | PTGES (0.42) | FFAR1PTGESPPARDPPARAMTNR1A | |
| SCHEMBL5045150 | 0.85 | FFAR1 (0.47) | FFAR1PTGESPTGDR2ACACBPSMB5 | |
| SCHEMBL1854015 | 0.83 | PTGES (0.38) | FFAR1PTGESPPARDPPARAMTNR1A | |
| SCHEMBL5140004 | 0.83 | PTGES (0.35) | FFAR1PTGESPPARDPPARAMTNR1A | |
| SCHEMBL1854016 | 0.81 | PTGES (0.35) | FFAR1PTGESPPARDPPARAMTNR1A | |
| SCHEMBL4974276 | 0.78 | MTNR1A (0.32) | FFAR1MTNR1AACACB | |
| SCHEMBL4670156 | 0.78 | PTPN11 (0.45) | FFAR1PTGESPTGDR2RORCPTPN11 | |
| SCHEMBL5039404 | 0.77 | ACACB (0.39) | FFAR1PTGESMTNR1AACACBPTPN11 | |
| SCHEMBL5044116 | 0.77 | FFAR1 (0.43) | FFAR1PSMB5RORCMCHR1 | |
| SCHEMBL5048897 | 0.77 | ACACB (0.35) | FFAR1MTNR1AACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | claimed |
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | LABORATORIES SERONO SA (CH) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207722-A1 | Glepp-1 Inhibitors in the Treatment of Autoimmune and/or Inflammatory Disorders | PPP1R1B, PPP5C, PPP3CA | FFAR1 2136/4885PTGES 999/4885PPARD 2645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.